Effect of EPBD in ERCP on the Prognosis of Patients With Choledocholithiasis Complicated With Duodenal Papillary Diverticula
EPBD
EPBD+Small EST VS. Large EST in Patients With Choledocholithiasis Complicated With Duodenal Papillary Diverticula
1 other identifier
interventional
128
1 country
1
Brief Summary
The investigators hypothesized that nipple balloon dilatation could make ERCP more successful and reduce postoperative complications and mortality. So the investigators design this experiment on this assumption.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable
Started Oct 2019
Shorter than P25 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
October 15, 2019
CompletedFirst Submitted
Initial submission to the registry
January 30, 2020
CompletedFirst Posted
Study publicly available on registry
February 5, 2020
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 15, 2020
CompletedStudy Completion
Last participant's last visit for all outcomes
August 15, 2020
CompletedFebruary 5, 2020
October 1, 2019
8 months
January 30, 2020
February 2, 2020
Conditions
Keywords
Outcome Measures
Primary Outcomes (3)
Incidence of complications
total complications occurded after operation
1 month
time of operation
duration of the ERCP
1-4 hours
postoperative recurrent rate
Recurrence rate of choledocholithiasis
1 year
Study Arms (2)
EPBD
EXPERIMENTALSmall incision of the duodenal nipple + EPBD
EST
ACTIVE COMPARATORLarge incision of the duodenal nipple
Interventions
Eligibility Criteria
You may qualify if:
- Patients with choledocholithiasis. 2. During ERCP, the patient was diagnosed as choledocholithiasis combined with duodenal papillary diverticulum. 3. Ages 16 to 75. 4. choledocholithiasis no larger than 1.5 cm
You may not qualify if:
- Patients with duodenal papillary tumor. 2. Pregnant. 3. Patients with gastrointestinal duct obstruction endoscopy who cannot be operated and who have endoscopic contraindications. 4. Patients with duodenoscopy contraindications. 5. Patients with severe pancreatitis and other serious diseases.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Renmin Hospital of Wuhan University
Wuhan, Hubei, 430060, China
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- TRIPLE
- Who Masked
- CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
January 30, 2020
First Posted
February 5, 2020
Study Start
October 15, 2019
Primary Completion
June 15, 2020
Study Completion
August 15, 2020
Last Updated
February 5, 2020
Record last verified: 2019-10
Data Sharing
- IPD Sharing
- Will not share